These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 18056711)
1. Mutation of Gly721 alters DNA topoisomerase I active site architecture and sensitivity to camptothecin. van der Merwe M; Bjornsti MA J Biol Chem; 2008 Feb; 283(6):3305-3315. PubMed ID: 18056711 [TBL] [Abstract][Full Text] [Related]
2. Alterations in linker flexibility suppress DNA topoisomerase I mutant-induced cell lethality. Losasso C; Cretaio E; Palle K; Pattarello L; Bjornsti MA; Benedetti P J Biol Chem; 2007 Mar; 282(13):9855-9864. PubMed ID: 17276985 [TBL] [Abstract][Full Text] [Related]
3. Domain interactions affecting human DNA topoisomerase I catalysis and camptothecin sensitivity. Fiorani P; Amatruda JF; Silvestri A; Butler RH; Bjornsti MA; Benedetti P Mol Pharmacol; 1999 Dec; 56(6):1105-15. PubMed ID: 10570037 [TBL] [Abstract][Full Text] [Related]
4. Substitution of conserved residues within the active site alters the cleavage religation equilibrium of DNA topoisomerase I. Colley WC; van der Merwe M; Vance JR; Burgin AB; Bjornsti MA J Biol Chem; 2004 Dec; 279(52):54069-78. PubMed ID: 15489506 [TBL] [Abstract][Full Text] [Related]
5. Active site mutations in DNA topoisomerase I distinguish the cytotoxic activities of camptothecin and the indolocarbazole, rebeccamycin. Woo MH; Vance JR; Marcos AR; Bailly C; Bjornsti MA J Biol Chem; 2002 Feb; 277(6):3813-22. PubMed ID: 11733535 [TBL] [Abstract][Full Text] [Related]
6. Substitutions of Asn-726 in the active site of yeast DNA topoisomerase I define novel mechanisms of stabilizing the covalent enzyme-DNA intermediate. Fertala J; Vance JR; Pourquier P; Pommier Y; Bjornsti MA J Biol Chem; 2000 May; 275(20):15246-53. PubMed ID: 10809761 [TBL] [Abstract][Full Text] [Related]
7. DNA topoisomerase I domain interactions impact enzyme activity and sensitivity to camptothecin. Wright CM; van der Merwe M; DeBrot AH; Bjornsti MA J Biol Chem; 2015 May; 290(19):12068-78. PubMed ID: 25795777 [TBL] [Abstract][Full Text] [Related]
8. Single mutation in the linker domain confers protein flexibility and camptothecin resistance to human topoisomerase I. Fiorani P; Bruselles A; Falconi M; Chillemi G; Desideri A; Benedetti P J Biol Chem; 2003 Oct; 278(44):43268-75. PubMed ID: 12904303 [TBL] [Abstract][Full Text] [Related]
9. Mechanisms of DNA topoisomerase I-induced cell killing in the yeast Saccharomyces cerevisiae. Fiorani P; Bjornsti MA Ann N Y Acad Sci; 2000; 922():65-75. PubMed ID: 11193926 [TBL] [Abstract][Full Text] [Related]
10. Molecular mechanism of the camptothecin resistance of Glu710Gly topoisomerase IB mutant analyzed in vitro and in silico. Tesauro C; Morozzo della Rocca B; Ottaviani A; Coletta A; Zuccaro L; ArnĂ² B; D'Annessa I; Fiorani P; Desideri A Mol Cancer; 2013 Sep; 12(1):100. PubMed ID: 24004603 [TBL] [Abstract][Full Text] [Related]
11. Intragenic suppressors of mutant DNA topoisomerase I-induced lethality diminish enzyme binding of DNA. Hann CL; Carlberg AL; Bjornsti MA J Biol Chem; 1998 Nov; 273(47):31519-27. PubMed ID: 9813066 [TBL] [Abstract][Full Text] [Related]
12. A single mutation in the 729 residue modulates human DNA topoisomerase IB DNA binding and drug resistance. Losasso C; Cretaio E; Fiorani P; D'Annessa I; Chillemi G; Benedetti P Nucleic Acids Res; 2008 Oct; 36(17):5635-44. PubMed ID: 18772225 [TBL] [Abstract][Full Text] [Related]
13. Mutation of Gly717Phe in human topoisomerase 1B has an effect on enzymatic function, reactivity to the camptothecin anticancer drug and on the linker domain orientation. Wang Z; D'Annessa I; Tesauro C; Croce S; Ottaviani A; Fiorani P; Desideri A Biochim Biophys Acta; 2015 Aug; 1854(8):860-8. PubMed ID: 25910424 [TBL] [Abstract][Full Text] [Related]
14. The human topoisomerase 1B Arg634Ala mutation results in camptothecin resistance and loss of inter-domain motion correlation. D'Annessa I; Tesauro C; Wang Z; ArnĂ² B; Zuccaro L; Fiorani P; Desideri A Biochim Biophys Acta; 2013 Dec; 1834(12):2712-21. PubMed ID: 24096022 [TBL] [Abstract][Full Text] [Related]
15. Molecular modeling studies of the DNA-topoisomerase I ternary cleavable complex with camptothecin. Fan Y; Weinstein JN; Kohn KW; Shi LM; Pommier Y J Med Chem; 1998 Jun; 41(13):2216-26. PubMed ID: 9632354 [TBL] [Abstract][Full Text] [Related]
16. Domains of human topoisomerase I and associated functions. Champoux JJ Prog Nucleic Acid Res Mol Biol; 1998; 60():111-32. PubMed ID: 9594573 [TBL] [Abstract][Full Text] [Related]
17. Locking the DNA topoisomerase I protein clamp inhibits DNA rotation and induces cell lethality. Woo MH; Losasso C; Guo H; Pattarello L; Benedetti P; Bjornsti MA Proc Natl Acad Sci U S A; 2003 Nov; 100(24):13767-72. PubMed ID: 14585933 [TBL] [Abstract][Full Text] [Related]
18. The human DNA topoisomerase I mutant Gly717Asp: Higher religation rate is not always associated with camptothecin resistance. Wang Z; D'Annessa I; Tesauro C; Ottaviani A; Soren BC; Dasari JB; Messina B; Thareparambil A; Fiorani P Arch Biochem Biophys; 2019 Mar; 663():165-172. PubMed ID: 30653963 [TBL] [Abstract][Full Text] [Related]
19. Disulfide cross-links reveal conserved features of DNA topoisomerase I architecture and a role for the N terminus in clamp closure. Palle K; Pattarello L; van der Merwe M; Losasso C; Benedetti P; Bjornsti MA J Biol Chem; 2008 Oct; 283(41):27767-27775. PubMed ID: 18693244 [TBL] [Abstract][Full Text] [Related]
20. Directed evolution to increase camptothecin sensitivity of human DNA topoisomerase I. Scaldaferro S; Tinelli S; Borgnetto ME; Azzini A; Capranico G Chem Biol; 2001 Sep; 8(9):871-81. PubMed ID: 11564555 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]